Is Bendamustine Hydrochloride Injection (Belrapzo) in shortage?
Bendamustine Hydrochloride Injection is listed by FDA as being discontinued by at least one maker (updated Nov 13, 2026).
Every listed package
FDA tracks shortages per package. What each maker reports, most recently updated first:
- Belrapzo, Injection, 100 mg/4 mL (25 mg/mL) (NDC 42367-521-25)
A business decision was made to discontinue manufacture of the drug.
Maker contact: 855-318-2170
FDA recalls of Bendamustine Hydrochloride
Recalls can cause or worsen a shortage. These FDA drug recalls share an active ingredient with Bendamustine Hydrochloride Injection:
Other forms on FDA’s list
Bendamustine Hydrochloride Injection shortage questions
Is Bendamustine Hydrochloride Injection (Belrapzo) in shortage?
Bendamustine Hydrochloride Injection is listed by FDA as being discontinued by at least one maker (updated Nov 13, 2026).
What should I do if I can’t get Bendamustine Hydrochloride Injection?
Don’t stop or ration it on your own. Ask your pharmacist whether another strength, package size or maker is in stock, and ask your prescriber about an alternative if none is.
Source: FDA Drug Shortages Database via openFDA. FDA notes that openFDA data is unvalidated and should not be used to make decisions about medical care; ask your pharmacist or prescriber before changing any medication. FDA Drug Shortages Database.